3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
86
Leukemia
50
Gastrointestinal Stromal Tumors
41
Leukemia, Myeloid, Chronic-Phase
28
Precursor Cell Lymphoblastic Leukemia-Lymphoma
25
Blast Crisis
17
Philadelphia Chromosome
13
Brain Neoplasms
12
Sarcoma
10
Leukemia, Myeloid, Acute
10
Glioblastoma
10
Lung Neoplasms
9
Leukemia, Myeloid, Accelerated Phase
9
Gliosarcoma
9
Prostatic Neoplasms
8
Neoplasms
7
Neoplasm Metastasis
7
Glioma
7
Oligodendroglioma
6
Melanoma
6
Leukemia, Myelomonocytic, Chronic
6
Dermatofibrosarcoma
6
Astrocytoma
6
Small Cell Lung Carcinoma
5
Recurrence
5
Primary Myelofibrosis
5
Polycythemia Vera
5
Ovarian Neoplasms
5
Leukemia, Myeloid
5
Central Nervous System Neoplasms
5
Interventions
tipifarnib
1
peginterferon alfa-2b
1
nilotinib
1
mirdametinib
1
binimetinib
1
Vincristine
1
Temozolomide
1
Sirolimus
1
Ranibizumab
1
Radiosurgery
1
Mn-PyC3A
1
Imatinib Mesylate
1
Everolimus
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neurofibroma
×
Imatinib Mesylate
×
Clear all
NCT01140360
2017-07-02
0908-09
Indiana University
Phase 1/2
Completed
21 enrolled
8 charts